Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vitespen |
Synonyms | |
Therapy Description |
Oncophage (vitespen) is a cancer vaccine that uses gp96 as an antigen, which may induce immune response against tumor cells expressing gp96 (PMID: 11727524). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vitespen | Oncophage|HSPPC-96 | Oncophage (vitespen) is a cancer vaccine that uses gp96 as an antigen, which may induce immune response against tumor cells expressing gp96 (PMID: 11727524). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02452281 | Phase Ib/II | Vitespen Ipilimumab | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | Withdrawn | USA | 0 |